Sign in
TerminatedPhase 1/2

Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia

Key facts

Who runs it
Reema Padia
Where
Pittsburgh, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
65 people enrolled
Started
18 Nov 2020
Ended
17 May 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Famotidine
  • Speech Language Therapy
Record updated
20 July 2025
Why it stopped
Slow recruitment due to few eligible patients

Who can take part

Age
0 months to 6 months
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Pediatric patients ages 0 to 6 months who do need meet the criteria at the initial appointment for supraglottoplasty
  • Seen in University of Pittsburgh Medical Center (UPMC) Children's Hospital of Pittsburgh (CHP) Otolaryngology Department
  • Laryngomalacia without prolonged (>20 seconds) cyanosis, apnea, nor failure to thrive

Who cannot take part

  • Patients with symptoms that necessitate surgery
  • Patients with a prior cardiac surgery
  • Patients with lung disease
  • Laryngomalacia with prolonged (>20 seconds) cyanosis, apnea, and failure to thrive
  • Patients with a syndrome
  • Patients with AST prescribed prior to the initial otolaryngology consult
  • Children over the age of 6 months old will be excluded from participation
  • Premature infants (<37 weeks gestation)
  • Sleep induced laryngomalacia
  • Patients with craniofacial abnormalities
  • Patients with additional airway abnormalities, seen before or at consult

Where in United States

  • UPMC Children's Hospital of PittsburghPittsburgh, United States

About the trial

What the trial wants to find out

Laryngomalacia (LM) is the most common cause of stridor in infants. Symptoms of gastroesophageal reflux (GER) are often seen in the setting of LM; therefore, acid suppression therapy (AST) has been empirically used in the management of this disorder. The investigators recently performed a retrospective chart review assessing improvement of airway and dysphagia symptoms, weight gain, and need for surgery with AST. It was found that there was a similar improvement between LM severity groups and most patients received AST (96.6%). It is unclear if these improvements are due to AST or natural resolution of the disease. With heightened concerns of side effects related to AST in infants, particularly among those born prematurely, judicious use of these medications is needed. The investigators are now performing a prospective study looking at the outcome differences in patients with laryngomalacia who are evaluated by speech language therapy (SLP) alone versus those with SLP evaluation and acid suppression therapy (famotidine).

The 2 groups in the trial

  • Speech Language Therapy AloneTreatment being tested

    Patients in this group will receive a routine swallowing evaluation by a speech language pathologist. Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.

    Treatment: Speech Language Therapy

  • Speech Language Therapy and Acid Suppression TherapyExisting treatment, for comparison

    Patients in this group will receive a routine swallowing evaluation by a speech language pathologist and famotidine (acid suppression therapy). Patient caregivers will fill out the Infant Gastroesophageal Reflux Questionnaire (I-GERQ-R) and the Pittsburgh Airway Symptom Score (PASS) the day of the appointment and at the 3-month follow up appointment.

    Treatment: Famotidine and Speech Language Therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
20 July 2025